Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin

Journal of Histochemistry and Cytochemistry

Volumn 49, Issue 6, 2001, Pages 791-792

  Shin, J S ^a   Stopyra, G A ^a   Warhol, M J ^a   Multhaupt, H A B ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Flow cytometry; Immunophenotyping; Mitosis; Plasmacytoma

Indexed keywords

CELL MARKER; CYTOKERATIN;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CLONAL ANERGY; FLOW CYTOMETRY; GAMMOPATHY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MITOSIS; MOLECULAR CLONING; NATURAL KILLER CELL; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 0034976179     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1177/002215540104900613     Document Type: Article

References (11)

1. The use of biological variables to predict outcome in multiple myeloma
2. Markers of multiple hematopoietic cell lineages in multiple myeloma
3. Myelomonocytic antigen positive multiple myeloma
4. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms
5. Frequent expression of haemopoietic and non-haemopoietic antigens by neoplastic plasma cells: An immunohistochemical study using formalin-fixed, paraffin-embedded tissue
6. Cell surface markers in multiple myeloma
7. The "CD43 only" phenotype. An aberrant, nonspecific immunophenotype requiring comprehensive analysis for lineage resolution
8. IgD myeloma/immunoblastic lymphoma cells expressing cytokeratin
9. Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma
10. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1;Leu-19)
11. Immunoreactive cytokeratins in plasmacytomas